KRAS G12A

BI-2493 / BI-2865: non-covalent inhibitors, binding the inactive state of KRAS, blocked the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. @Boehringer #LCSM https://t.co/7m549MX20c (@HHorinouchi)

The Frequency of Specific #KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer. 🇪🇸 🇪🇺 G12A incidence, though! @manjuggm @fireflyann @afm1003 @udai_banerji https://t.co/WE7F1kImFv (@CrozrX)

A 12-11 One more trial!! Pan #RAS G12i Ph I/Ib 📌https://t.co/xNGnaEYbli 📌n=141 📌RMC6326 📌For KRAS G12A/G12D/ G12R/ G12S or G12V mutant #CRC & other solid tumors 📌Primary end points: DLT, Safety 📌Trial open in the US https://t.co/2y2vpJDmAH #CRCTrialsChat #CRCSM (@manjuggm)

Any ideas what to offer to a patient with NSCLC with KRAS G12A mutation which has progressed on all kinds of immune and chemotherapy? (@cczielinski)

#TTLC22 P14 by Dr. @JessBoyceMD characterizes patients with NSCLC and soft tissue metastases (skin, muscle). Majority had #KRAS mutations (esp G12A) and that has definitely been my own experience. Curious about what is driving the tropism here. (@StephenVLiu)

As you can see in this #ovariancancer #LGSOC presentation, response across multiple #KRAS variants and WT, among them G12A top right corner. Not aware of that specific mutation response in other cancers for this comprehensive #MAPK #FAKi #KRAS platform. (@CrozrX)

🙌🏾 to open at @IntMedatIowa few days. While #pancreascancer #PANCSM is the major cohort, the vaccine 💉 is for multiple KRAS mutations. So #lcsm #HPBCSM #cholangiocarcinoma #CRCSM and I believe #ovariancancer. Using the #ctDNA @NateraOncology. G12D G12R G12V G12A G12C G12S G13D (@pashtoonkasi)

#KRAS #lungcancer variants G12V G12D G12A WT @IASLC @LungCancerEu @GO2Foundation @ALKLungCancer @lcrf_org @LUNGevity Dr. Ross Camidge discusses launch of #RAMP202 Vs-6766 /Defactinib registrational clinical study (RAF/MEKi -FAKi) @dave6408 @SarahCannonDocs https://t.co/U33fPMonYL (@CrozrX)

I'll dare to put in little diversity in here! ☺#wizard @udai_banerji accomplishment in a fantastic RAF •MEKi efficacy, DOR and safety profile in KRAS •G12V •G12D •G12A •WT variants! Amazing breakthrough in #LGSOC #NSCLC #PancreaticCancer #CRC #LessIsMore #IntermittentDosing (@CrozrX)

Promising multiple KRAS variants platform in dual RAF •MEK inhibitor VS-6766 (RO5126766) FAKi •Defactinib. G12V G12D G12A WT, giant leap in KRAS development! Efficacy, durability, safety profile! @udai_banerji is a wizard! @JackWestMD #NSCLC #PDAC #CRC #LGSOC (@CrozrX)

Not just G12C, but G12V •G12D •WT •G12A KRAS variants #NSCLC #LGSOC #PancreaticCancer #PDAC #CRC Vs-6766 /Defactinib https://t.co/KpdKLDWdLq (@CrozrX)

It's not only G12C with KRAS breakthrough data, but also G12D G12V G12A WT.. which bears major implications for pancreatic cancer, CRC, MM.. Also, synergistic combo with AMG510 in KRAS G12C. Phenomenal 65% ORR, 4% TEAE! Expanding cohorts.. https://t.co/VDN8PpGNsm (@CrozrX)

65% ORR, 4% TEAE across G12D G12V WT G12A.. KRAS variants. LGSOC cohort expansion to pancreatic cancer, CRC, NSCLC. Also great synergy with AMG510 KRAS G12C. https://t.co/VDN8PpYoQW (@CrozrX)